| Literature DB >> 32928833 |
Su Yun Chung1,2, Janice Gloria Shen1,2, Cristina M Ghiuzeli3,2.
Abstract
Recent studies have shown that BRAF inhibitors, such as vemurafenib, are effective in inducing long periods of remission in relapsed hairy cell leukaemia. Acute pancreatitis is one of the rare complications that is reported with vemurafenib use. As severe pancreatitis can be life threatening, physicians should be vigilant of this side effect and promptly treat patients that develop clinical signs and symptoms while receiving vemurafenib. We present an interesting case of vemurafenib-induced pancreatitis that not only resolved but also did not recur after reintroduction of the drug at a reduced dose. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: haematology (drugs and medicines); malignant and benign haematology; pancreatitis; safety; unwanted effects / adverse reactions
Mesh：
Substances：
Year: 2020 PMID： 32928833 PMCID： PMC7490934 DOI： 10.1136/bcr-2020-236073
Source DB: PubMed Journal: BMJ Case Rep ISSN： 1757-790X